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Endothelial function is thought to be an important factor in the pathogenesis of atheroscle-
rosis, hypertension and heart failure. In the 1990s, high-frequency ultrasonographic imaging
of the brachial artery to assess endothelium-dependent flow-mediated vasodilation (FMD)
was developed. The technique provokes the release of nitric oxide, resulting in vasodilation
that can be quantitated as an index of vasomotor function. The noninvasive nature of the
technique allows repeated measurements over time to study the effectiveness of various
interventions that may affect vascular health. However, despite its widespread use, there are
technical and interpretive limitations of this technique. State-of-the-art information is
presented and insights are provided into the strengths and limitations of high-resolution
ultrasonography of the brachial artery to evaluate vasomotor function, with guidelines for its
research application in the study of endothelial physiology. (J Am Coll Cardiol 2002;39:
257–65) © 2002 by the American College of Cardiology
The vascular endothelium is a large paracrine organ that
secretes numerous factors regulating vascular tone, cell
growth, platelet and leukocyte interactions and thromboge-
nicity. The endothelium senses and responds to a myriad of
internal and external stimuli through complex cell mem-
brane receptors and signal transduction mechanisms, lead-
ing to the synthesis and release of various vasoactive,
thromboregulatory and growth factor substances. Endothe-
lial dysfunction is thought to be an important factor in the
development of atherosclerosis, hypertension, and heart
failure. Over the past decade, a noninvasive technique has
evolved to evaluate flow-mediated vasodilation (FMD), an
endothelium-dependent function, in the brachial artery
(1–4). This stimulus provokes the endothelium to release
nitric oxide (NO) with subsequent vasodilation that can be
imaged and quantitated as an index of vasomotor function.
This technique is attractive because it is noninvasive and
allows repeated measurements. However, despite its wide-
spread use, there are technical and interpretive limitations.
This report presents state-of-the-art information in this
area of research and provides insights into the strengths and
limitations of this attractive and evolving technique.
PHYSIOLOGY OF FMD
The capacity of blood vessels to respond to physical and
chemical stimuli in the lumen confers the ability to self-
regulate tone and to adjust blood flow and distribution in
response to changes in the local environment. Many blood
vessels respond to an increase in flow, or more precisely
shear stress, by dilating. This phenomenon is designated
FMD. A principal mediator of FMD is endothelium-
derived NO.
The precise mechanisms for the acute detection of shear
forces and subsequent signal transduction to modulate
vasomotor tone are not fully understood. The endothelial
cell membrane contains specialized ion channels, such as
calcium-activated potassium channels, that open in response
to shear stress (5–7). The effect of potassium channel
opening is to hyperpolarize the endothelial cell, increasing
the driving force for calcium entry (there are no voltage-
gated calcium channels in endothelial cells). Calcium acti-
vates an enzyme, endothelial nitric oxide synthase (eNOS),
and the subsequent generation of NO appears to account for
FMD (8,9). Indeed, endothelial denudation or treatment
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with a nitric oxide synthase (NOS) inhibitor abolishes
FMD in a variety of arterial vessels. However, it was
recently shown that blood vessels from mice genetically
engineered to lack the eNOS enzyme (eNOS knockout
mice) still respond to shear stress by dilating (10). In the
eNOS knockout mice, FMD seems to be mediated by
endothelium-derived prostanoids, as it is blocked by indo-
methacin (10). Thus, there is some redundancy in the
system, and more than one endothelial mediator is capable
of acting as the signal between endothelium and smooth
muscle. It is unknown whether other mediators, such as the
putative endothelium-derived hyperpolarizing factor, can
cause FMD if both NO and prostanoids are deficient.
Several mechanisms may underlie the increase in NO in
response to changes in shear stress. Very acute changes may
be mediated by the increase in intracellular calcium that
occurs when ion channels open (see the previous text). Over
slightly longer time periods (minutes), shear-stress-induced
phosphorylation of eNOS via a serine/threonine protein
kinase, Akt/PKB, increases eNOS activity, even at low
calcium concentrations, and this may be important to allow
continued output of NO (11,12). In addition, other post-
translational modifications of the enzyme (myristilation or
palmitoylation) or interaction with caveolin can affect intra-
cellular localization of the enzyme and thereby alter its
function. Over longer time periods (many minutes or
hours), eNOS gene transcription is activated, and this can
result in continued increases in NO generation if shear
stress is maintained at high levels.
TECHNIQUE
Subject preparation. Numerous factors affect flow-
mediated vascular reactivity, including temperature, food,
drugs and sympathetic stimuli, among others. Therefore,
subjects should fast for at least 8 to 12 h before the study,
and they should be studied in a quiet, temperature-
controlled room. All vasoactive medications should be
withheld for at least four half-lives, if possible. In addition,
subjects should not exercise, should not ingest substances
that might affect FMD such as caffeine, high-fat foods and
vitamin C or use tobacco for at least 4 to 6 h before the
study. The investigator should be cognizant of the phase of
the subject’s menstrual cycle, as it too may affect FMD (13).
All of these confounding factors must be considered in
preparing a subject in studies that seek to determine the
impact of a single intervention. For observational cohort
studies, data must be collected on those factors known to
affect the measurement of FMD, and analysis should
address their impact (14–16).
Equipment. Ultrasound systems must be equipped with
vascular software for two-dimensional (2D) imaging, color
and spectral Doppler, an internal electrocardiogram (ECG)
monitor and a high-frequency vascular transducer. A linear
array transducer with a minimum frequency of 7 MHz,
attached to a high-quality mainframe ultrasound system, is
used to acquire images with sufficient resolution for subse-
quent analysis. Image resolution is enhanced with broad-
band (multiple-frequency: 7 to 12 MHz) linear array trans-
ducers. Timing of each image frame with respect to the
cardiac cycle is determined with simultaneous ECG record-
ing on the ultrasound system video monitor.
Image acquisition. The subject is positioned supine with
the arm in a comfortable position for imaging the brachial
artery. The brachial artery is imaged above the antecubital
fossa in the longitudinal plane (Fig. 1). A segment with
clear anterior and posterior intimal interfaces between the
lumen and vessel wall is selected for continuous 2D gray-
scale imaging. Currently, cross-sectional imaging of the
brachial artery cannot be used to determine maximum
diameter or area of the lumen because of inadequate image
definition of the lateral walls. Also, skew artifacts from
cross-sectional imaging limit accurate diameter determina-
tion. In addition to 2D grayscale imaging, both M mode
and A mode (wall tracking) can be used to continuously
measure the diameter (17,18), yet these techniques may be
more subject to error owing to tracking drift. No direct
comparison has been made of diameter determinations from
continuous recording using grayscale images versus wall
tracking. During image acquisition, anatomic landmarks
such as veins and fascial planes are noted to help maintain
the same image of the artery throughout the study. A
stereotactic probe-holding device can be helpful.
Endothelium-dependent FMD. To create a flow stimulus
in the brachial artery, a sphygmomanometric (blood pres-
sure) cuff is first placed either above the antecubital fossa or
on the forearm. A baseline rest image is acquired, and blood
flow is estimated by time-averaging the pulsed Doppler
velocity signal obtained from a midartery sample volume.
Thereafter, arterial occlusion is created by cuff inflation to
suprasystolic pressure. Typically, the cuff is inflated to at
least 50 mm Hg above systolic pressure to occlude arterial
inflow for a standardized length of time. This causes
ischemia and consequent dilation of downstream resistance
vessels via autoregulatory mechanisms. Subsequent cuff
deflation induces a brief high-flow state through the bra-
chial artery (reactive hyperemia) to accommodate the di-
lated resistance vessels. The resulting increase in shear stress
causes the brachial artery to dilate. The longitudinal image
of the artery is recorded continuously from 30 s before to
2 min after cuff deflation. A midartery pulsed Doppler
signal is obtained upon immediate cuff release and no later
than 15 s after cuff deflation to assess hyperemic velocity.
Abbreviations and Acronyms
ECG  electrocardiogram/electrocardiographic
eNOS  endothelial nitric oxide synthase
FMD  flow-mediated vasodilation
NO  nitric oxide
NOS  nitric oxide synthase
NTG  nitroglycerin
2D  two-dimensional
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Studies have variably used either upper arm or forearm
cuff occlusion, and there is no consensus as to which
technique provides more accurate or precise information
(Fig. 2, schematic drawing). When the cuff is placed on the
upper part of the arm, reactive hyperemia typically elicits a
greater percent change in diameter compared with that
produced by the placement of the cuff on the forearm
(19–21). This may be due to a greater flow stimulus
resulting from recruitment of more resistance vessels or
possibly to direct effects of ischemia on the brachial artery.
However, upper-arm occlusion is technically more challeng-
ing for accurate data acquisition as the image is distorted by
collapse of the brachial artery and shift in soft tissue. The
change in brachial artery diameter after cuff release increases
as the duration of cuff inflation increases from 30 s to 5 min.
The change in diameter is similar after 5 and 10 min of
occlusion; therefore, the more easily tolerated 5-min occlu-
sion is typically used. Also, FMD may be studied in the
radial, axillary and superficial femoral arteries. Notable
caveats are that arteries smaller than 2.5 mm in diameter are
Figure 1. Ultrasound image of the brachial artery (longitudinally) at 8 magnification, 11-MHz transducer frequency annotated for anatomic landmarks.
Figure 2. Schematic drawing of ultrasound imaging of the brachial artery with upper versus lower cuff placement and transducer position above the
antecubital fossa. BP  blood pressure; FMD  flow-mediated vasodilation.
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difficult to measure, and vasodilation is generally less diffi-
cult to perceive in vessels larger than 5.0 mm in diameter
(4,17,22).
Endothelium-independent vasodilation with nitroglycer-
in. At least 10 min of rest is needed after reactive hyper-
emia (i.e., FMD) before another image is acquired to reflect
the reestablished baseline conditions. In most studies to
date, an exogenous NO donor, such as a single high dose
(0.4 mg) of nitroglycerin (NTG) spray or sublingual tablet
has been given to determine the maximum obtainable
vasodilator response, and to serve as a measure of
endothelium-independent vasodilation reflecting vascular
smooth muscle function (23). Peak vasodilation occurs 3 to
4 min after NTG administration; images should be contin-
uously recorded during this time, and NTG should not be
administered to individuals with clinically significant bra-
dycardia or hypotension. Determining the vasodilator re-
sponses to increasing doses of NTG, rather than a single
dose, may further elucidate changes in smooth muscle
function or arterial compliance that might be playing a role
in any observed changes in FMD.
ANALYSIS
Accurate analysis of brachial artery reactivity is highly
dependent on the quality of ultrasound images.
Anatomic landmarks. The diameter of the brachial artery
should be measured from longitudinal images in which the
lumen-intima interface is visualized on the near (anterior)
and far (posterior) walls (Fig. 1). These boundaries are best
visualized when the angle of insonation is perpendicular.
Thus, clear visualization of both the near and far wall
lumen-intima boundaries indicates that the imaging plane is
bisecting the vessel in the longitudinal direction, and diam-
eters measured from these images likely reflect the true
diameter. Once the image for analysis is chosen, the
boundaries for diameter measurements (the lumen-intima
or the media-adventitia interfaces) are identified manually
with electronic calipers or automatically using edge-
detection software. The variability of the diameter measure-
ment is greatest when it is determined from a point-to-
point measurement of a single frame, and least when there
is an average derived from multiple diameter measurements
determined along a segment of the vessel (Fig. 3).
Similarly, cross-sectional images are less reliable, for only
a single point in the vessel’s length is used to determine
maximal diameter. The diameter measurement along a
longitudinal segment of vessel is dependent upon the
alignment of the image. Skew occurs when the artery is not
completely bisected by the plane of the ultrasound beam.
With slight skew, the maximal diameter measured is con-
stant, and thus yields a more accurate measurement. Some
edge-detection programs can account for skew from trans-
ducer angulation (17,18).
Timing of FMD. Flow-mediated vasodilation is an
endothelium-dependent process that reflects the relaxation
of a conduit artery when exposed to increased shear stress.
Increased flow, and thereby increased shear stress, through
the brachial artery occurs during postocclusive reactive
hyperemia. Several studies have suggested that the maximal
increase in diameter occurs approximately 60 s after release
of the occlusive cuff, or 45 to 60 s after peak reactive
hyperemic blood flow (20,22). The increase in diameter at
this time is prevented by the NOS inhibitor NG-monomethyl-
L-arginine, indicating that it is an endothelium-dependent
process mediated by NO (24,25). Other measures of vaso-
dilator response include time to maximum response (26),
duration of the vasodilator response (27) and the area under
the dilation curve (28).
Timing of the measurement during the cardiac cycle.
Brachial artery diameter should be measured at the same
time in the cardiac cycle, optimally achieved using ECG
gating during image acquisition. The onset of the R-wave is
used to identify end diastole, and the peak of the T-wave
reproducibly identifies end systole. Peak systolic diameter is
larger than end systolic diameter, because the vessel expands
during systole to accommodate the increase in pressure and
volume generated by left ventricular contraction. The mag-
nitude of systolic expansion is affected by the vessel com-
pliance, and it may be reduced by factors such as aging and
hypertension (possibly by reduced bioavailability of NO).
Thus, functional characteristics of the brachial artery may
obfuscate the measurement of FMD if diameter is measured
during end systole; however, this concern has not been
tested in a rigorous trial.
Characterizing FMD. Flow-mediated vasodilation is typ-
ically expressed as the change in post-stimulus diameter as a
percentage of the baseline diameter (3). Baseline diameter
influences percent change in two ways. First, for any given
absolute change in the postflow stimulus diameter, a larger
baseline diameter yields a smaller measure of percent
change. Reporting absolute change in diameter will mini-
mize this problem. Second, smaller arteries appear to dilate
relatively more than do larger arteries (3). Both factors merit
consideration when comparing vasodilator responses be-
tween individuals and groups with different baseline diam-
eters. For studies in which comparisons are made before and
after an intervention in the same individuals, percent change
might be the easiest method to use if baseline diameter
remains stable over time. However, the best policy may be
to measure and report baseline diameter, absolute change
and percent change in diameter.
TRAINING AND QUALITY IMPROVEMENT
Despite its deceptively simple appearance, ultrasonographic
assessment of brachial artery reactivity is technically chal-
lenging and has a significant learning curve. The elements
necessary to ensure optimal implementation of the tech-
nique are outlined in Table 1. Ideally, an individual trained
in the principles and technical aspects of 2D and Doppler
ultrasonography would perform the technique. The learning
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curve typically requires several months and depends both on
the technical skill of the individual and the frequency with
which the technique is performed. Optimal training in the
technique requires hands-on training by an experienced
individual who can demonstrate the pitfalls and ultrasound
artifacts and who can delineate manual techniques and
optimal ultrasonography system parameters.
Thorough training in the technique helps to establish
high quality and consistency in the method and data. An
important component of training and protocol development
is attention to ergonomic issues. The operator should sit in
a comfortable position and support the arm holding the
probe. Both the quality of the images and the measurements
rely on steady transducer imaging of the brachial artery
while minimizing stress-related fatigue and injuries. It is
recommended that at least 100 supervised scans and mea-
surements be performed before independent scanning and
reading is attempted; 100 scans per year should be per-
formed to maintain competency. This recommendation is
based in part on criteria for ultrasound proficiency estab-
lished by the Intersocietal Commission for the Accredita-
tion of Vascular Laboratories. Ongoing feedback from the
Figure 3. Ultrasound image of the brachial artery at (A) baseline and (B) 1 min after hyperemic stimulus.
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trainer and review of videotapes showing recorded brachial
artery vasoactivity testing provide valuable education. Cri-
teria for acceptable image quality for optimal FMD mea-
surements set a useful standard to qualify brachial artery
studies for research protocols.
Evaluating precision of the technique. Intraobserver and
interobserver variability in image acquisition and analysis
should be established and periodically reassessed for each
condition, including baseline, reactive hyperemia and NTG
administration. Image variability is best judged by having
two sonographers independently scan the same series of
subjects at different times. The highest reproducibility is
likely to be shown over a short interval, during which the
individual vasodilator response is unlikely to have changed
owing to environmental or other influences. This can be
accomplished by taking two measurements on the same day
within a 10- to 15-min interval, or on separate days in
otherwise identical circumstances. Longitudinal studies in
which interventions over weeks to months are tested require
that reproducibility measurements be performed at longer
intervals. The image analysis and measurement of the
vasodilator response from repeated studies should be per-
formed by an individual who is blinded as to sequence.
Measurement variability is assessed, typically, by a desig-
nated core laboratory for multicenter trials, prior to site
certification and periodically thereafter to analyze for tem-
poral drifts.
Several approaches exist to describe the differences in any
Table 1. Training and Quality Improvement Protocol
Elements Scanning Measurement
Manuals Subjects: written procedure description
Sonographers:
Succinct protocol flow sheet at station
Longer protocol documentation manual
Explicit written measurement protocol documentation
to enhance consistency
Manual and automated measurements:
Frame and segment selection
Criteria for unmeasurable studies
Worksheets Record subject factors: Log book to track status of studies
If ineligible, why Worksheet to record technical quality of study
Potential FMD modifiers (e.g., food)
Blood pressure and cuff inflation pressure
Record-scan factors
Training Scientific Rationale and Physiology of FMD
Basic knowledge of ultrasound equipment, two-dimensional and
Doppler analysis
Demonstrate technical tips and pitfalls
Qualification criteria
Training period with close supervision and feedback
Formal observer-specific reproducibility assessment
Ergonomic issues
Qualification criteria
Training period with close supervision
Periodic review of scan performance
Minimum number of studies:
At least 100 supervised scans prior to scanning independently
At least 100 scans per year to maintain competency
Minimum number of studies:
At least 100 supervised scans prior to scanning
independently
All observers from a given study measure 100
studies together prior to reading independently
At least 100 scans per year to maintain
competency
Reproducibility Image variability
In single-site study, each sonographer scans the same
participants to assess for systematic differences
Multisite studies should have core reading laboratory,
intra- and interobserver variability, temporal variability
Statistics
Correlations, mean and absolute differences, components of variability (systematic vs. random differences)
Assess on baseline and peak deflation diameters and FMD. Doppler, if assessed.
Descriptive Statistics Assess for systematic differences by sonographer and by site Assess for systematic differences by observer and by site
Routine Studies
Mean baseline and peak deflation diameters and FMD. Doppler data, if reported.
Per time period and over time to assess for secular drifts in measurements
Data Cleaning Missing worksheet or measurement data
Criteria to re-evaluate study: range checks, consistency checks
Laboratory Meetings Periodic laboratory meetings
Review work flow, compliance with scan and measurement protocols
Measure random and difficult studies together
Review results of data cleaning and reproducibility analyses
Education Initial training is most efficiently gained by visiting experienced laboratories
The field would benefit from the availability of more formal course opportunities
Certification Although noninvasive measurement of endothelial function is a research tool, certification will remain study-specific
Prior to becoming a clinical tool, formal certification requirements, courses and ongoing continuing medical education will be
necessary
FMD  flow-mediated vasodilation.
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two sets of measurement results. One is the correlation
coefficient, which is derived from data that represent the
entire range of measurements anticipated in the setting in
which the technique will be employed. A second metric is
simply the mean and range of differences between the measures,
which gives an intuitive understanding of the lower limits of
differences that can meaningfully be ascribed to variation
between subjects or secondary to intervention. The third
metric, the coefficient of variation, is intended to communi-
cate the size of the variance of a measure relative to the
mean value of what is being measured. Because FMD is a
percentage-ratio measure, small differences between observ-
ers appear very large.
There is no single ideal measurement to assess reproduc-
ibility of this technique. A scatterplot showing results
obtained at time one and time two along with the line of
identity, accompanied by the results of the three metrics
described in the previous text, is likely the most complete
way to describe reproducibility of FMD of the brachial
artery. Rigorous attention to protocol standardization,
training and ongoing quality improvement is critical to
generating valid, reproducible data.
APPLICATION IN CLINICAL TRIALS
Assessment of FMD of the brachial artery in clinical trials
has increased because of its seeming ease of use, efficiency
and noninvasive nature. Owing to the biological and tech-
nical variability of the measurement, several caveats should
be considered when planning a clinical trial where FMD is
the end point of interest. These include study design,
sample size and uniform technique.
Study design. Recent studies have reported on the effect of
pharmacologic or physiologic interventions on FMD of the
brachial artery. These include both acute (16,29,30) and
longer-term intervention trials (31–33). Both parallel-group
and crossover designs have been successfully employed.
Implications of approach for sample size determinations
have been reported (4). The majority of studies to date have
been from single institutions, but multicenter studies are
now being reported (34). Multicenter studies require one
site serving as the core laboratory to ensure uniform meth-
odology, as previously discussed.
Sample size. Typically, significant improvement in FMD
can be seen with 20 to 30 patients in a crossover design
study and 40 to 60 patients in a parallel-group design study.
In studies of this size, the minimal statistically significant
improvement that can be detected with intervention is an
absolute change in FMD of 1.5% to 2%. The sample size
depends greatly on the variance of repeated measurement in
the control group in a particular vascular laboratory; the
power of the study should be based on the group’s control
data. This is particularly important in order to exclude type
II error in negative studies.
With intervention trials, an important parameter to
report is the time-dependent reproducibility of FMD. For
example, in the placebo group, the pretreatment and
postintervention FMD measures are usually reported, and
often are very similar. However, if the mean difference
between the two measurements for each patient is quite
high, it indicates that the variance of the technique might
limit interpretation of the study results. An acceptable
reproducibility is a mean difference of 2% to 3% in FMD
over time (on a baseline vasodilation of about 10%) (4). This
value has not been readily available in published trials.
Methodology. As discussed above, several techniques have
been employed to measure FMD (35,36). Laboratories
should select the method that gives them the most repro-
ducible results, and for multicenter studies, the same scan-
ning protocol should be employed at all sites.
For studies employing repeated measurements following
intervention, FMD might change as a result of the inter-
vention. However, FMD could also be affected by a change
in the hyperemic stimulus. Therefore, the flow stimulus
should be consistent. Otherwise, any change in FMD of the
conduit artery may be related to changes in flow (indirectly
mediated by changes in the microcirculation) rather than
improvement of endothelial function of the conduit vessel
per se. As such, peak hyperemic flows, as reflected by the
Doppler velocity measurement, should be reported. Another
potential factor that might confound interpretation of FMD
is the baseline diameter. If the baseline diameter changes, the
resulting percent change in diameter might be affected. For
example, a large increase (10%) in baseline diameter
might result in a decrease in FMD that is a result of the
change in resting tone, not the effect of the intervention on
endothelial function.
FUTURE DIRECTIONS
Ultrasound assessment of brachial artery FMD has yielded
important information about vascular function in health and
disease, yet several new approaches and technological ad-
vances have emerged. Most prior studies examined FMD at
a single time point, typically 1 min after cuff release. This
practice evolved from the observations that the maximal
dilator response occurs at approximately 1 min in healthy
subjects (22) and that the necessity for manual acquisition
and measurement placed a practical limit on the number of
image frames that could be analyzed.
Commercially available technology now makes it possible
to acquire multiple images of the brachial artery automati-
cally using the ECG signal as a trigger and to measure
arterial diameter automatically using computer-based edge-
detection techniques. This approach allows investigators to
examine the entire time course of brachial dilation in
response to reactive hyperemia (Fig. 4), the true peak
response, the time to peak and the overall duration of FMD
as discussed in the previous text. The time course and extent
of brachial expansion within a single cardiac cycle, possibly
reflecting vessel compliance, can be examined. In the carotid
artery, compliance has been shown to correlate with cardio-
263JACC Vol. 39, No. 2, 2002 Corretti et al.
January 16, 2002:257–65 Guidelines for Measuring FMD
vascular risk (37). About 70% of the dilation observed 1 min
after cuff release is attributable to NO synthesis (24).
Further studies are needed to evaluate other vasoactive
mechanisms and to determine whether various disease states
influence the kinetics and/or extent of FMD.
Careful examination of the vasodilator response to NTG
provides another potential avenue for investigation. Al-
though most studies have detected little effect of disease
states on this response, there is evidence that cardiovascular
risk factors might impair the vasodilator response to NTG
(38), especially when a dose-response curve is measured
(39). These findings are consistent with experimental stud-
ies demonstrating that inactivation of NO by reactive
oxygen species is an important mechanism of vascular
dysfunction (40). Further information about the causes of
vascular dysfunction and the response to interventions may
be gained by examining the response to a submaximal dose
of NTG or a series of NTG doses.
The effect of disease states and/or interventions on the
blood flow response to cuff occlusion (reactive hyperemia) is
underexplored. Current technology limits the utility of
spectral Doppler to reproducibly assess changes in flow,
which might provide useful information about endothelial
function of the microvasculature.
Tremendous interest exists in determining the clinical
utility of brachial artery FMD. Investigators have hypoth-
esized that endothelial function may serve as an integrating
index of risk factor burden and genetic susceptibility, and
that endothelial dysfunction will prove to be a preclinical
marker of cardiovascular disease (41). Several studies sug-
gest that the presence of endothelial dysfunction in the
coronary circulation is an independent predictor of cardio-
vascular disease events (42,43). Ongoing studies in several
large populations, including the Framingham Heart Study
and the Cardiovascular Health Study, shall determine
whether endothelial dysfunction in the brachial artery will
identify patients at risk for developing coronary artery
disease, cerebral vascular disease and/or peripheral vascular
disease. The technique is particularly well suited for study of
the earliest stages of atherosclerosis in children and young
adults, thus providing maximal opportunity for prevention.
Numerous studies have demonstrated that brachial artery
reactivity improves with risk factor modification and treat-
ment with drugs known to reduce cardiovascular risk. It
remains unknown whether an improvement in endothelial
function directly translates into improved outcome. In the
future, however, practitioners may use brachial artery FMD
to assess response to drug therapy and to individualize
patient risk factor modification programs. Further studies
are needed to determine whether the methodology is
sufficiently reproducible and whether biological variability is
sufficiently low to make assessment of FMD a clinically
useful measure of cardiovascular risk on an individual or
group basis. To that end, the methodology will need to
mature, with formal opportunities for training, certification
and continuing medical education, as currently exist for
other cardiovascular testing modalities.
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